相关实验视频
Updated: Mar 19, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
临床更新: 糖尿病中的心血管疾病: 动脉样性心血管疾病和2型糖尿病中的心力衰竭 - 机制,管理和临床考虑
Cecilia C Low Wang1, Connie N Hess1, William R Hiatt1
1From Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Colorado School of Medicine, Aurora (C.C.L.); CPC Clinical Research, Aurora, CO (C.C.L., C.N.H., W.R.H.); Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora (C.N.H., W.R.H.); Joslin Diabetes Center, and Harvard Medical School, Boston, MA (A.B.G.).
心血管疾病是糖尿病患者的主要风险. 目前的治疗改善了结果,但不能完全解决糖尿病患者心脏病的潜在机制.
科学领域:
- 心脏病学
- 内分泌学
- 药理学
背景情况:
- 心血管疾病是糖尿病患者死亡和残疾的主要原因.
- 糖尿病加速动脉样硬化和心力衰竭,但目前的血糖控制策略是不够的.
- 尽管多因素降低了风险,但糖尿病患者心血管疾病并发症率仍然很高.
研究的目的:
- 审查糖尿病心血管疾病管理的机制,历史背景和争议.
- 评估目前心血管管理指南的新药物和最新证据.
- 支持基于证据的治疗急性疾病以外的糖尿病患者.
主要方法:
- 关于机制,历史和争议的文献评论.
- 对糖尿病和心血管疾病的新药物分析.
- 检查最近的证据和目前的心血管管理的指导方针.
主要成果:
- 现有的治疗策略不足以调节糖尿病加剧的心血管疾病机制.
- 多因素降低风险显示有好处,但并不能消除糖尿病中心血管疾病风险的增加.
- 新的药物药物和更新的指导方针提供了更好的管理选择.
结论:
- 仅仅优化血糖控制不足以预防糖尿病的心血管并发症.
- 应对多因素风险的综合管理至关重要.
- 包括新药在内的基于证据的策略对于改善糖尿病患者的心血管结果至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Cardiomyopathy II: Dilated Cardiomyopathy
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

